Foclivia

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

površinski antigeni virusa influence, inaktivirani: A / Viet Nam / 1194/2004 (H5N1)

Available from:

Seqirus S.r.l. 

ATC code:

J07BB02

INN (International Name):

pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)

Therapeutic group:

Cepiva proti gripi

Therapeutic area:

Influenza, Human; Immunization; Disease Outbreaks

Therapeutic indications:

Preprečevanje gripe v uradno prijavljeni pandemični situaciji. Pandemije gripe cepiva je treba uporabljati v skladu z uradnimi smernice.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2009-10-18

Patient Information leaflet

                                67
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v hladilniku. Ne zamrzujte. Shranjujte v originalni
ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Zavrzite v skladu z lokalnimi predpisi.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Seqirus S.r.l.
Via del Pozzo 3/A, S. Martino
53035 Monteriggioni (SI)
Italija.
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/09/577/001 1 napolnjena injekcijska brizga z iglo
EU/1/09/577/002 10 napolnjenih injekcijskih brizg z iglo
EU/1/09/577/005 1 napolnjena injekcijska brizga brez igle
EU/1/09/577/006 10 napolnjenih injekcijskih brizg brez igle
13.
ŠTEVILKA SERIJE
Številka serije
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna
68
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
69
PODATKI NA ZUNANJI OVOJNINI
KARTONASTA ŠKATLA ZA VIALO Z ENIM ODMERKOM
1.
IME ZDRAVILA
Foclivia suspenzija za injiciranje
cepivo proti pandemični gripi (površinski antigeni, inaktivirani, z
adjuvansom)
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
En odmerek (0,5 ml) vsebuje učinkovine: površinski antigeni
(hemaglutinin in nevraminidaza),
namnoženi v oplojenih kokošjih jajcih iz jat zdravih piščancev, z
dodanim adjuvansom MF59C.1, seva
virusa influence:
A/Vietnam/1194/2004 (H5N1)
7,5 mikrogramov hemaglutinina
Adjuvans: MF59C.1 emulzija olja v vodi, ki vsebuje skvalen kot oljno
fazo in je stabilizirana s
polisorbatom 80 in sorbitantrioleatom v citratnem pufru (natrijev
citrat, citronska kislina).
3.
SEZNAM POMOŽNIH SNOVI
Natrijev klorid, kalijev klorid, kalijev dihidrogenfosfat, natrijev
hidrogenfosfat dihidrat, magnezijev
klorid heksahidrat, k
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Foclivia suspenzija za injiciranje v napolnjeni injekcijski brizgi
cepivo proti pandemični gripi (H5N1) (površinski antigen,
inaktiviran, z adjuvansom)
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Površinski antigeni (hemaglutinin in nevraminidaza)* naslednjega seva
virusa influence:
A/Vietnam/1194/2004 (H5N1)
7,5 mikrogramov**
na odmerek 0,5 ml
*
namnoženi v oplojenih kokošjih jajcih iz jat zdravih piščancev
**
izraženo v mikrogramih hemaglutinina.
Adjuvans MF59C.1 vsebuje:
skvalen
9,75 miligramov
polisorbat 80
1,175 miligramov
sorbitantrioleat
1,175 miligramov
natrijev citrat
0,66 miligramov
citronska kislina
0,04 miligramov
Cepivo je skladno s priporočili SZO in odločbo EU za pandemijo.
Cepivo Foclivia lahko vsebuje sledi jajc in piščančjih beljakovin,
ovalbuminov, kanamicinijevega
sulfata, neomicinijevega sulfata, formaldehida, hidrokortizonov in
cetiltrimetilamonijevega bromida,
ki se uporabljajo v proizvodnem procesu (glejte poglavje 4.3).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
suspenzija za injiciranje v napolnjeni injekcijski brizgi
mlečno bela tekočina
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Profilaksa influence pri uradno razglašeni pandemiji.
Zdravilo Foclivia je treba uporabljati v skladu z uradnimi smernicami.
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Osebe, stare 6 mesecev ali več: uporabite dva odmerka (po 0,5 ml),
presledek med njima naj bo
21 dni.
Podatki o tretjem odmerku (obnovitvenem) 6 mesecev po prvem odmerku so
omejeni (glejte
poglavji 4.8 in 5.1).
3
Pediatrična populacija
Podatki pri otrocih, starih od 6 mesecev do 17 let, so opisani v
poglavju 5.1.
Podatki pri otrocih, starih do 6 mesecev, niso na voljo.
Način uporabe
Cepivo se daje z intramuskularnim injiciranjem, po možnosti v
anterolateralni predel stegna pri
dojenčkih ali v predel deltoidne mišice nadlakti pri starejših
osebah.
4.3
KONTRAINDIKACIJE
Anafilaktične (tj. smrtno nevarne) reakcije v anamnezi 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 03-10-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 03-10-2023
Public Assessment Report Public Assessment Report Bulgarian 25-09-2019
Patient Information leaflet Patient Information leaflet Spanish 03-10-2023
Public Assessment Report Public Assessment Report Spanish 25-09-2019
Patient Information leaflet Patient Information leaflet Czech 03-10-2023
Public Assessment Report Public Assessment Report Czech 25-09-2019
Patient Information leaflet Patient Information leaflet Danish 03-10-2023
Public Assessment Report Public Assessment Report Danish 25-09-2019
Patient Information leaflet Patient Information leaflet German 03-10-2023
Public Assessment Report Public Assessment Report German 25-09-2019
Patient Information leaflet Patient Information leaflet Estonian 03-10-2023
Public Assessment Report Public Assessment Report Estonian 25-09-2019
Patient Information leaflet Patient Information leaflet Greek 03-10-2023
Public Assessment Report Public Assessment Report Greek 25-09-2019
Patient Information leaflet Patient Information leaflet English 03-10-2023
Public Assessment Report Public Assessment Report English 25-09-2019
Patient Information leaflet Patient Information leaflet French 03-10-2023
Public Assessment Report Public Assessment Report French 25-09-2019
Patient Information leaflet Patient Information leaflet Italian 03-10-2023
Public Assessment Report Public Assessment Report Italian 25-09-2019
Patient Information leaflet Patient Information leaflet Latvian 03-10-2023
Public Assessment Report Public Assessment Report Latvian 25-09-2019
Patient Information leaflet Patient Information leaflet Lithuanian 03-10-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-10-2023
Public Assessment Report Public Assessment Report Lithuanian 25-09-2019
Patient Information leaflet Patient Information leaflet Hungarian 03-10-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 03-10-2023
Public Assessment Report Public Assessment Report Hungarian 25-09-2019
Patient Information leaflet Patient Information leaflet Maltese 03-10-2023
Public Assessment Report Public Assessment Report Maltese 25-09-2019
Patient Information leaflet Patient Information leaflet Dutch 03-10-2023
Public Assessment Report Public Assessment Report Dutch 25-09-2019
Patient Information leaflet Patient Information leaflet Polish 03-10-2023
Public Assessment Report Public Assessment Report Polish 25-09-2019
Patient Information leaflet Patient Information leaflet Portuguese 03-10-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 03-10-2023
Public Assessment Report Public Assessment Report Portuguese 25-09-2019
Patient Information leaflet Patient Information leaflet Romanian 03-10-2023
Public Assessment Report Public Assessment Report Romanian 25-09-2019
Patient Information leaflet Patient Information leaflet Slovak 03-10-2023
Public Assessment Report Public Assessment Report Slovak 25-09-2019
Patient Information leaflet Patient Information leaflet Finnish 03-10-2023
Public Assessment Report Public Assessment Report Finnish 25-09-2019
Patient Information leaflet Patient Information leaflet Swedish 03-10-2023
Public Assessment Report Public Assessment Report Swedish 25-09-2019
Patient Information leaflet Patient Information leaflet Norwegian 03-10-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 03-10-2023
Patient Information leaflet Patient Information leaflet Icelandic 03-10-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 03-10-2023
Patient Information leaflet Patient Information leaflet Croatian 03-10-2023
Public Assessment Report Public Assessment Report Croatian 25-09-2019

View documents history